A phase II trial of denileukin diftitox in patients with previously treated advanced non-small cell lung cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 32, Issue 3, 2009, Pages 269-273

  Gerena Lewis, Margie ^a   Crawford, Jeffrey ^b   Bonomi, Philip ^c   Maddox, Ann Marie ^d   Hainsworth, John ^e   McCune, David E ^f   Shukla, Rakesh ^a   Zeigler, Haoyue ^a   Hurtubise, Paul ^a   Chowdhury, Tracy R ^a   Fletcher, Brandon ^a   Dyehouse, Karyn ^a   Ghalie, Richard ^g   Jazieh, Abdul R ^a,h  

^a UNIVERSITY OF CINCINNATI   (United States)

^b DUKE UNIVERSITY   (United States)

^c Cardiology Department   (United States)

^d UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^e SARAH CANNON RESEARCH INSTITUTE   (United States)

^f MADIGAN ARMY MEDICAL CENTER   (United States)

^g Ligand Pharmaceutical   (United States)

^h Department of Oncology ^*  (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

DENILEUKIN DIFTITOX; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; ERLOTINIB; GEFITINIB; PARACETAMOL; PLATINUM DERIVATIVE; SODIUM CHLORIDE;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOPSY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PAIN; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CATHETER INFECTION; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONSTIPATION; DEHYDRATION; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENERALIZED PAIN; HEART EDEMA; HEMOPTYSIS; HUMAN; HYPOTENSION; INDUCED HYPOTENSION; INSOMNIA; LETHARGY; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LUNG SURGERY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; MYOCARDITIS; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRURITUS; REPEATED DRUG DOSE; SIDE EFFECT; SURVIVAL TIME; SYMPTOM; TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; TREMOR; VASCULAR DISEASE; VASCULAR LEAK SYNDROME; WEAKNESS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DIPHTHERIA TOXIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INTERLEUKIN-2; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECOMBINANT FUSION PROTEINS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67749142288     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318187dd40     Document Type: Article

References (21)

1. Cancer Stat Facts Sheet National Cancer Institute Surveillance Epidemiology and End Results. http:/www.SEER.Cancer.gov/statfacts/html/lungb. html.
2. Miniami Y, Kono T, Miyazaki T, et al. The IL-2 receptor complex: its structure, function and target genes. Annu Rev Immunol. 1993;11:245.
3. Nakase K, Kita K, Nasu K, et al. Differential expression of interleukin-2 receptors (alpha and beta chain) in mature lymphoid neoplasms. Am J Hematol. 1994;46:179-183.
4. Robb RJ, Greene WC. Internalization of interleukin-2 is mediated by the beta chain of the high-affinity interleukin-2 receptor. J Exp Med. 1987;165:1201- 1206.
5. Kiyokawa T, Williams DP, Snider CE, et al. Protein engineering of diphtheria-toxin-related interleukin-2 fusion toxins to increase cytotoxic potency for high-affinity IL-2-receptor-bearing target cells. Protein Eng. 1991;4:463- 468.
6. Foss FM. DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology. Clin Lymphoma. 2000;1(suppl 1):S27-S31.
7. Poulakis N, Sarandakou A, Rizos D, et al. Soluble interleukin-2 receptors and other markers in primary lung cancer. Cancer. 1991;68:1045-1049.
8. Naumnik W, Chczewska E. The clinical significance of serum soluble interleukin 2 receptor (sIL2R) concentration in lung cancer. Folia Histochem Cytobiol. 2001;39(suppl 2):S185-S186.
9. Ginns LC, De Hoyos A, Brown MC, et al. Elevated concentration of soluble interleukin-2 receptors in serum of smokers and patients with lung cancer. Correlation with clinical activity. Am Rev Respir Dis. 1990;142:398-402.
10. Tisi E, Lissoni P, Angeli M, et al. Postoperative increase in soluble interleukin-2 receptor serum levels as predictor for early recurrence in non-small cell lung carcinoma. Cancer. 1992;69:2458-2462.
11. Kawashima O, Kamiyoshihara M, Sakata S, et al. The clinicopathological significance of preoperative serum soluble interleukin-2 receptor concentrations in operable non-small cell lung cancer patients. Ann Surg Oncol. 2000;7:239-245.
12. Yano T, Yoshino I, Yokoyama H, et al. The clinical significance of serum soluble interleukin-2 receptors in lung cancer. Lung Cancer. 1996;15:79-84.
13. Yano T, Fukuyama Y, Yokoyama H, et al. Interleukin-2 receptors in pulmonary adenocarcinoma tissue. Lung Cancer. 1996;16:13-19.
14. Shepherd F, Rodriguez Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-132.
15. Fossella F, Devore R, Kerr R, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum containing chemotherapy regimens. J Clin Oncol. 2000;18:2354-2362.
16. Fossella F, Lee J, Shin D, et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer. J Clin Oncol. 1995;13:645-651.
17. Barnett B, Kryczek I, Cheng P, et al. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am JReprod Immunol. 2005;54:369-377.
18. + T cells in tumors from patients with early-stage NSCLC and late-stage ovarian cancer. Cancer Res. 2001;61:4766-4772.
19. Woo EY, Yeh H, Chu C, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol. 2002;168:4272-4276.
20. + regulatory T-lymphocytes: current concepts and therapeutic potential. J Soc Biol. 2002;196:263-266 [in French].
21. Yakirevich E, Resnick M. Regulatory T-lymphocytes: pivotal components of the host antitumor response. J Clin Oncol. 2007;125:2506-2508.